Home World News Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of... World News Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 775 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Hormone Therapy Has A Stronger Impact On A Woman’s Quality Of... October 16, 2019 Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... October 22, 2019 Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... October 17, 2019 Load more HOT NEWS Breaking the silence: when cancer steals your voice High Risk of BCSM at 20 Years in Men with Hormone... Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with...
